Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Lupus Nephritis

• An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
• Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
• A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
• A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
• UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
• Safety and Efficacy of ONT01 in Lupus
• A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
• A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
• Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis
• A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
• SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis
• A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
• MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
• A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
• Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis
• Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
• CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
• A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
• Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
• Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
• Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
• US Zamto-cel Autoimmune Diseases
• NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
• Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
• NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1)
• A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
• A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
• Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus Nephritis
• Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
• A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
• A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
• A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
• A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)
• A Phase 1 Study of ADI-001 in Autoimmune Disease
• KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
• The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
• Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
• AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
• A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
• SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
• Assessment of Safety and Efficacy of SGLT2is Among LN Patients
• A Study of Felzartamab in Participants With Lupus Nephritis
• RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
• Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
• Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
• Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis
• An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Autoimmune Disorders
• A Phase 2b Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
• Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
• An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases.
• The Effect of Curcumin on the Clinical Outcome of Pediatric Patients With Active Lupus Nephritis
• SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
• A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Telitacicept in Lupus Nephritis
• The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN
• Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
• Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis
• The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
• MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN
• Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis
• Voclosporin in Adolescents With Lupus Nephritis
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
• Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
• Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
• VIBRANT: VIB4920 for Active Lupus Nephritis
• Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
• Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
• Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis
• Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis
• A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
• Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
• A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis
• Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation
• Daratumumab to Treat Active Lupus Nephritis
• Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
• Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
• Comparison between2 Drugs in Lupus Nephritis
• A Study of Guselkumab in Participants With Active Lupus Nephritis
• Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis
• A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
• Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis
• Metformin In Prevention of Lupus Nephritis
• Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
• An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
• Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis
• Mesenchymal Stromal Cells (MSC´s) in Renal Lupus
• Pentoxifylline in Lupus Nephritis
• Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
• Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
• Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
• Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)
• Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
• Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
• A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
• An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
• Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis
• Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis
• Aurinia Renal Response in Active Lupus With Voclosporin
• The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis
• Aurinia Early Urinary Protein Reduction Predicts Response
• Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
• The Iguratimod Effect on Lupus Nephritis (IGeLU)
• Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
• Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis
• Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis
• A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
• Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
• A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis
• The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear
• Rituximab and Belimumab for Lupus Nephritis
• A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis
• ACTHar in the Treatment of Lupus Nephritis
• Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
• AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
• A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis
• BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis
• ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
• The Effect of Calcitriol on Progress and Activity of Lupus Nephritis
• Phase Ib Study of SC Milatuzumab in SLE
• Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis
• Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
• RING - Rituximab for Lupus Nephritis With Remission as a Goal
• Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis
• Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
• Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
• Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
• Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis
• BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
• A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
• Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil
• A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients
• Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis
• A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients
• Clinical Trial Treatment in Lupus Nephritis
• Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis
• An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
• Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
• Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
• Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis
• Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis
• Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
• Velcade for Proliferative Lupus Nephritis
• Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
• Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis
• Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis
• The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
• Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study
• Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria
• Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
• To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis
• Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis
• Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
• Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
• Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg
• A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
• Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis
• The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
• A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis
• Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis
• The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria
• Etanercept for the Treatment of Lupus Nephritis
• Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study
• A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
• Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
• A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis
• A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
• A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
• Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
• TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
• To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN
• Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)
• A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
• Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone
• Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.
• Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
• Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
• Study of LJP 394 in Lupus Patients With History of Renal Disease
• Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
• BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
• Cyclophosphamide and Fludarabine to Treat Lupus Nephritis